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Abstract
 
Mice lacking the p110
 
 
 
 catalytic subunit of phosphatidylinositol 3-kinase have reduced numbers
of B1 and marginal zone B cells, reduced levels of serum immunoglobulins, respond poorly to
immunization with type II thymus-independent antigen, and are defective in their primary and
 
secondary responses to thymus-dependent antigen. p110
 
 
 
 
 
/
 
 
 
 B cells proliferate poorly in
response to B cell receptor (BCR) or CD40 signals in vitro, fail to activate protein kinase B, and
are prone to apoptosis. p110
 
 
 
 function is required for BCR-mediated calcium flux, activation
of phosphlipaseC
 
 
 
2, and Bruton’s tyrosine kinase. Thus, p110
 
 
 
 plays a critical role in B cell
homeostasis and function.
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Introduction
 
B lymphocyte development, selection, and activation are
critically dependent on signal transduction events mediated
by the B cell antigen receptor (BCR)
 
*
 
 (1). The BCR is
tightly associated with nonpolymorphic subunits, CD79a
and b, which contain immunoreceptor tyrosine–based
activation motifs. Immunoreceptor tyrosine–based activation
motifs serve to recruit tyrosine kinases of the Src and Syk
families that initiate the signal transduction cascade by
phosphorylation of multiple substrate proteins (2).
A number of studies have provided evidence for a role
for phosphatidylinositol 3-kinase (PI3-K) and the second
messenger phosphatidylinositol 3,4,5-trisphosphate (PIP-3)
in BCR signal transduction. PI3-K is activated downstream
of the BCR for antigen (3, 4) and the CD19 coreceptor (5,
6). The class IA PI3-K’s consist of three catalytic subunits
p110
 
 
 
, 
 
 
 
, and 
 
 
 
 that are encoded by distinct genes and inter-
act with a family of adaptor proteins that regulate location
and enzyme activity (7). Mice deficient in the p85
 
 
 
 or
p85/p55/p50
 
 
 
 adaptor proteins (8, 9) of PI3-K display an
immune defect similar to 
 
xid
 
 mice in which the Pleckstrin
homology domain of Bruton’s tyrosine kinase (Btk) can no
longer bind PIP-3 (10). Btk, a member of the TEC family
of tyrosine kinases, is thought to be a major effector of
PI3-K in B cells. Btk acts, in part, to regulate calcium
flux through the phosphorylation and activation of
 
phospholipaseC
 
 
 
2 (PLC
 
 
 
2; reference 11). The regulation
of Btk membrane association and activation by phos-
phoinositides plays an important role in regulating B cell
responses (12).
B cells from mice deficient in the breakdown of PIP-3,
such as those lacking the SH2 domain-containing inositol
polyphosphate 5
 
 
 
-phosphatase 1, display accelerated develop-
ment and are hyperresponsive to BCR stimulation (13–15).
Furthermore, mice deficient in the phosphatase and tensin
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Abbreviations used in this paper: 
 
BCAP, B cell adapter for PI3-K; BCR,
B cell antigen receptor; Btk, Bruton’s tyrosine kinase; IP3, inositol 3,4,5
trisphosphate; MZ, marginal zone; PI3-K, phosphatidylinositol 3-kinase;
PIP-3, phosphatidylinositol 3,4,5 trisphosphate; PKB, protein kinase B;
PLC
 
 
 
2, phospholipaseC
 
 
 
2; TD, thymus-dependent antigen; RF, recir-
culating follicular. 
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homolog gene that encodes a PIP-3 3
 
 
 
 phosphatase de-
velop B cell hyperplasia, lymphoma, and hypergamma-
globulinaemia (16).
Each of the three class IA catalytic subunits of PI3-K are
expressed in B cells, however their relative roles in B cell de-
velopment and function are unknown. Mutant mice lacking
p110
 
 
 
 (17) and p110
 
 
 
 (18) have previously been reported to
have lethal phenotypes that precluded analysis of immune
cell development and function. p110
 
 
 
 is the most recently
identified PI3-K catalytic subunit with expression reported
to be highest in hematopoietic cells (19, 20). We have used
gene-targeting to generate mice that lack p110
 
 
 
 function.
Our analysis of B cell development in these mice revealed an
essential role for p110
 
 
 
 in the development of B1 and mar-
ginal zone (MZ) B cells. Furthermore, B cell responses to
thymus-dependent and -independent antigens required
p110
 
 
 
 function. Analysis of BCR signal transduction re-
vealed an important role for p110
 
 
 
 in the regulation of pro-
liferation and calcium flux. These defects can be attributed to
a failure to activate protein kinase B (PKB) and Btk.
 
Materials and Methods
 
Generation of p110
 
 
 
 Knockout Mice.
 
The structure of murine
 
pik3cd
 
 genomic clones isolated from a 129/Sv genomic library has
been described previously (21). The targeting vector consists of
LoxP flanked neomycin and hygromycin-resistance cassettes
cloned 7.5 kb apart into the EcoRV and XhoI sites respectively
of the 
 
pik3cd
 
 genomic clone. This strategy was adopted in an at-
tempt to generate a conditional allele of 
 
pik3cd
 
. The targeting
vector was transfected into PC3 mouse embryonic stem cells (22)
and analyzed for the targeting event using Southern blotting of
KpnI-digested DNA with probe A (a 700-bp EcoRI fragment).
Correctly targeted clones were injected into blastocysts to pro-
duce chimaeric mice. The resulting chimaeras, which express the
Cre enzyme in the male germline (22), were bred to obtain lines
of mice harboring a 
 
pik3cd
 
 gene which had undergone Cre-medi-
ated recombination and thus deleted exons 1–9 encoding the first
490 amino acids of p110
 
 
 
. These were detected by Southern blot
analysis using KpnI-digested DNA and by PCR. All mice were
bred at the Babraham Institute Small Animal Barrier Unit
(SABU) and housed according to UK Home Office guidelines
under project licence 80/1263. p110
 
 
 
-deficient mice were born
in normal Mendelian ratios from heterozygous intercrosses and
were fertile and healthy under SPF conditions.
 
Measurement of PIP-3 Levels.
 
Lipid extracts were assayed from
stimulated B cells after precipitation with 0.5 M trichloroacetic
acid. A time resolved fluorescence resonance energy transfer
ligand displacement assay was performed using the general recep-
tor for phosphoinositides-1 Pleckstrin homology domain as a
PIP-3–specific binding protein (23) (unpublished data).
 
Immunoprecipitation and Western Blot Analysis.
 
Purification of
splenic B cells, immunoprecipitation and Western blotting were
performed using previously described methods (24). B cell purity
was around 95% as assessed by flow cytometry of lymphocytes (un-
published data). Antibodies to Btk provided by V. Tybulewicz
(National Institute for Medical Research, London, UK), antisera
against, amino acids 74–89 of murine p110
 
 
 
 and against the
COOH-terminal 20 amino acids of murine PLC
 
 
 
2 were from
(Babraham Technix), anti–Vav-1 (24), phospho-Btk (25), have
been described previously. Phospho-I
 
 
 
B
 
 
 
, phospho-PKB, and
 
pan-PKB were from Cell Signaling Technology, p110
 
 
 
 (H-201),
p110
 
 
 
 (S-19) IkB
 
 
 
 (C-21) were from Santa Cruz Biotechnology,
Inc., anti–Bcl-XL was from BD Transduction Laboratories, anti-
p85
 
 
 
 was from Upstate Biotechnology, anti-PLC
 
 
 
2 PY 759 anti-
body will be described previously (unpublished data).
 
Immunofluorescence Staining of Tissue Sections.
 
Spleens were har-
vested and immediately frozen by dipping in liquid nitrogen.
Spleens were mounted in OCT and 8-
 
 
 
m sections were cut, air-
dried, and stored at –20
 
 
 
C until use. Sections were fixed in ice-
cold acetone for 15 min, air-dried briefly, rehydrated in PBS and
then blocked with 5% normal rat serum for 15 min. Sections
were stained with FITC-conjugated MOMA-1 antibody (rat
IgG2a; Serotec), and biotinylated anti-IgM (clone R6–60.2, rat
IgG2a; BD BioSciences), or control FITC-conjugated rat IgG2a
(BD BioSciences) for 1 h at room temperature. Sections were
washed in PBS and stained with a 1:200 dilution of streptavidin-
TRITC (Jackson ImmunoResearch Laboratories) for 1 h. Sec-
tions were washed and mounted in Aqua PolyMount (Polysciences,
Inc.) and viewed with an Olympus BX-40 epifluorescence mi-
croscope using appropriate filters. Images were digitally captured
using a high-resolution CCD camera (F-View) using analySIS
 
®
 
software (SIS, GmbH) and processed using Adobe Photoshop
 
®
 
v.7.0.
 
Antibody Responses.
 
Staining of cells with fluorescent anti-
bodies was performed as described previously (24). All antibodies
were purchased from BD PharMingen except anti–IgM-Cy5
and anti-IgD-PE (Jackson ImmunoResearch Laboratories). Se-
rum Igs in naive mice were determined by ELISA using anti-
bodies purchased from BD PharMingen. For immune responses,
8-wk-old mice were injected intraperitoneally with either 5 
 
 
 
g
DNP-Ficoll in a solution of PBS or 50 
 
 
 
g DNP conjugated to
KLH in a solution of PBS. Serum antibody levels were deter-
mined by ELISA as described previously (24). The relative units
of DNP-specific antibodies are shown as optical density values.
A dilution series of the serum samples was measured and for each
isotype a single dilution factor which fell in the linear part of the
curve is represented for all time points. Serum dilution factors
were as follows: thymus-independent responses 1:800 for IgM
and 1:800 for IgG
 
3
 
. For thymus-dependent responses, the dilu-
tions were 1:800 for IgM, IgG
 
2b
 
, and IgG
 
3
 
, 1:1,600 for IgG
 
1
 
, and
1:200 for IgG
 
2a
 
.
 
B Cell Proliferation and Apoptosis Assays.
 
Purified B cells were
cultured for 72 h at an initial concentration of 10
 
6
 
 cells per milli-
liter with the indicated doses of polyclonal anti-IgM or mono-
clonal anti-IgM (clone B7.6), monoclonal anti-CD40 (clone 3/23)
and recombinant murine IL-4 in RPMI 1640 supplemented
with 10% FCS, 2 mM
 
 
 
L
 
-glutamine, 100 U/ml penicillin, 100
 
 
 
g/ml streptomycin, and 5 
 
 
 
 10
 
 
 
5 
 
M 2-mercaptoethanol. Prolif-
eration was measured by incorporation of [
 
3
 
H]thymidine follow-
ing a 16-h pulse. For analysis of apoptosis, B cells were cultured
in the above media but without antibodies or IL-4 and apoptosis
determined by flow cytometry of permeabilized cells stained with
propidium iodide as described previously (26).
 
Calcium Flux Analysis.
 
Purified splenic B cells were loaded
for 30 min at RT in the dark with 3 
 
 
 
M Fluo-4 a.m. (Molecular
Probes) at a density of 6 
 
  
 
10
 
6
 
 cells per milliliter in 0.5% BSA/
PBS. The cells were washed in indicator free medium and then
resuspended at 3 
 
  
 
10
 
6
 
 cells per milliliter in 0.5% BSA/PBS con-
taining 1 mM CaCl
 
2
 
. After a further incubation of 30 min to al-
low complete deesterification of intracellular Fluo-4 a.m. ester,
the variations in absorbance were measured using a Perkin-Elmer
LS55 Luminescence Spectrometer. [Ca
 
2
 
 
 
]
 
i
 
 was calculated as de-
scribed previously (27). 
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Results
 
Impaired BCR Stimulated PIP-3 Production in the Absence of
p110
 
 
 
.
 
To address the function of p110
 
 
 
 in B cells, we
used gene targeting to produce p110
 
 
 
 null mice (Fig. 1, A
and B). Thymocytes and B cells from these mice lacked
p110
 
 
 
 protein (Fig. 1 C and unpublished data). B cells from
control and mutant mice expressed similar levels of p110
 
 
 
and p110
 
 
 
 catalytic subunits, but showed a small reduction
in the levels of the p85
 
 
 
 and P55/p50
 
 
 
 adaptor subunits
(Fig. 1 D). To determine the impact of this mutation on
BCR-induced PIP-3 production we employed a novel assay
that permits determination of PIP-3 levels in primary cells,
without the need for biosynthetic labeling. We observed that
BCR-stimulated B cells from p110
 
 
 
-deficient mice pro-
duced little PIP-3 (Fig. 1, E and F). In control B cells, PIP-3
levels peaked after 1 min of BCR stimulation and returned
to baseline by 10 min, in mutant mice no increases in PIP-3
levels were observed within 10 min of stimulation (Fig. 1 F).
These data indicate p110
 
 
 
 was responsible for most of the
BCR-induced PIP-3 production.
 
B1 and MZ B Cells Require p110
 
 
 
..
 
Flow cytometric anal-
ysis of the bone marrow of p110
 
 
 
 
 
/
 
 
 
 
 
mice did not reveal
any major blocks in B cell development (Table I). How-
ever, we observed a marked reduction in the B1 subset res-
ident in the peritoneal cavity (Fig. 2 A and Table I). Fur-
thermore, CD21
 
hi
 
 CD23lo MZ B cells of the spleen were
also significantly reduced in number (Fig. 2 B and Table I).
This conclusion was further supported by noting the ab-
sence of the splenic B220  CD1high population in the mu-
tants (unpublished data). Examination of frozen splenic tis-
sue sections stained with anti-IgM and anti–MOMA-1
(which stains MZ metallophilic-macrophages), revealed
that in the p110  mutant there were very few B cells be-
yond the marginal sinus (delineated by MOMA-1 staining),
supporting the conclusion that the MZ B cell population
was severely reduced. The number of conventional B2 B
cells was significantly reduced in young p110  /  mice
(Table I). By contrast, older p110  /  mice had only mar-
ginally reduced numbers of B2 cells (Table I). Subdivision
Figure 1. p110  mutant B cells fail to produce PIP-3. (A) Gene targeting strategy. (B) Southern blot
analysis of tail DNA from wild-type ( / ), heterozygous ( / ), and homozygous ( / ) mutant
mice using probe A. (C) Western blot analysis of wild-type, heterozygous, and homozygous mutant
thymocytes using antibody against p110 . The blot was reprobed with anti–Vav-1 to demonstrate equal
protein loading. (D) Western blot analysis of wild-type and homozygous mutant B-lymphocytes for
levels of p110 , p110 , the p85/55/50  subunits of PI3-K, and PLC 2. (E) BCR stimulated PIP-3
production in wild-type and mutant B cells. Wild-type is represented by black bars, mutant by white
bars. (F) Time course of PIP-3 production in wild-type and mutant B cells stimulated with 10  g/ml
anti-IgM F(ab)2. In E and F, error bars represent the variance of triplicate determinations.756 p110  in B Cell Homeostasis and Function
of splenic B cells using IgM and IgD staining revealed that
p110  /  mice had near normal numbers of IgMlo IgDhi B
cells, which are mature recirculating follicular (RF) B cells
(Fig. 2 B and Table I). The level of surface IgM staining on
follicular B cells was not different between control and mu-
tants mice (Fig. 2 B). Thymocyte development, and the
number of CD4 , CD8  T cells, and Mac1  macrophages
in the spleens of P110  /  mice were not different from
littermate controls (Table I and unpublished data).
Impaired Antibody Responses in p110  /  Mice. In non-
immunized P110  /  mice the levels of serum IgM, IgG1,
IgG2a, and IgG3 and were significantly reduced, whereas
IgG2b and IgA were in the normal range (Fig. 3 A). To de-
termine the ability of p110  /  mice to mount humoral re-
sponses, we immunized p110  /  mice with the T cell–
independent type II antigen, DNP-Ficoll. The hapten-specific
IgM response of p110  /  mice after immunization was sig-
nificantly reduced when compared with that of control
mice, similarly, the levels of DNP-specific IgG3 produced
were significantly lower in p110  /  mice (Fig. 3 B). The
primary response to thymus-dependent (TD) antigens was
measured 7 d after administration of DNP-KLH. Wild-type
littermate mice produced IgM, IgG1 IgG2a, IgG2b, and IgG3
antibodies against DNP (Fig. 3 C). By contrast, p110  / 
mice produced significantly less anti-DNP antibody of these
subclasses. By 21 d after the primary immunization antigen
specific Ig levels had generally fallen and reimmunization of
control animals with DNP-KLH led to a secondary re-
sponse. Although mice lacking p110  produced antigen-
specific Ig, there was a significant defect in the production
of antigen-specific Ig of all subclasses tested (Fig. 3 C). Anal-
ysis of germinal center formation in the spleen after immu-
nization revealed a reduction in the p110  /  mice (Fig. 3
D). Those germinal centers that were found were often
atypical in size or location (unpublished data). This defect
was underscored by a reduction in the number of Peyer’s
patches on the small intestine from 7.75   1.7 in control
mice (n   4) to 4   1.2 in p110  /  mice (n   4). Further-
more, the Peyer’s patches were smaller in the mutant mice
and staining of B lymphocytes with GL7, an activation anti-
gen expressed on germinal center B cells, also revealed a de-
fect in p110  /  mice (Fig. 3 E).
Impaired In Vitro Responses of p110  /  B Cells. Puri-
fied splenic B cells from p110 -deficient mice proliferated
poorly in response to in vitro stimulation with polyclonal
anti-IgM antibody, which is a potent B cell mitogen (Fig. 4
A). Supplementation of the media with IL-4 enhanced
proliferation in both wild-type and p110  /  B cells.
p110 -deficient B cells were also poorly responsive to
combinations of monoclonal anti-IgM, CD40, and IL-4
that elicited high levels of proliferation in control B cells
(Fig. 4 B). By contrast the proliferative response of the mu-
tant B cells to LPS was normal (Fig. 4 B). PKB is a PI3-K
effector that has been shown to be involved in growth con-
trol and the suppression of apoptosis (28). The activation of
PKB is an early, dose dependent, event after BCR engage-
ment in normal B cells, however we found PKB activation
was severely impaired in B cells from p110  /  mice (Fig.
4 C). While some PKB phosphorylation was evident in
mutant B cells at the highest doses of antibody used for
BCR stimulation, this phosphorylation was not sustained
(Fig. 4 D), suggesting PKB was only weakly and transiently
activated. When B cells from p110  /  mice were cultured
in serum containing media, the spontaneous level of apop-
tosis was increased when compared with wild-type (Fig. 4
E) suggesting survival pathways were defective. Survival
signaling through the BCR requires the activation of NF-
 B and subsequent induction of the prosurvival bcl-2 fam-
ily member Bcl-xL (29). NF- B activation requires the
phosphorylation of a cytoplasmic inhibitor (I B) by the
multiprotein (I B-kinase) IKK complex. This targets I B
for ubiquitination and subsequent degradation and permits
nuclear translocation of the transcription factor (30). We
measured activation of IKK after BCR stimulation using
antibodies specific to phosphorylated serine 32 of I B . In
control B cells there was a transient induction of phosphor-
Table I. Lymphocyte Populations in p110  /  Mice
Tissue/cell type Control p110  / 
Bone Marrowa
Fraction A–C 8.6   105 (2.7) 7.5   105 (1.5)
Fraction D 4.1   106 (1.3) 3.1   106 (0.8)
Fraction E 9.6   105 (4.0) 7.2   105 (1.4)
Fraction F 6.6   105 (2.4) 9.6   105 (4.2)
Spleen (8–10 wk old)
Large Mac1+ 1.5   106 (0.2) 1.2   106 (0.3)
CD4+ 2.5   107 (0.5) 2.5   107 (0.9)
CD8+ 1.3   107 (0.3) 1.1   107 (0.4)
CD21hi CD23lo 3.7   106 (0.8) 0.6   106 (0.05)b
B220+ 4.4   107 (1.3) 3.1   107 (0.7)
IgMhi IgDlo 3.6   106 (1.1) 2.6   106 (0.8)
IgMhi IgDhi 1.1   107 (0.3) 1.1   107 (0.2)
IgMlo IgDhi 2.6   107 (0.8) 1.6   107 (0.4)
Spleen (21-d old)
IgMhi IgDlo 2.7   106 (0.8) 106 (0.1)c
IgMhi IgDhi 9   106 (1.4) 2.2   106 (0.4)c
IgMlo IgDhi 3.2   106 (0.2) 0.8   106 (0.2)d
Peritoneum
B1 total 106 (0.2) 0.08   106 (0.02)c
B1a 2.4   105 (0.2) 0.1   105 (0.02)c
B1b 1.9   105 (0.3) 0.07   105 (0.01)c
B2 5.7   105 (2.9) 4.9   105 (3.6)
Values are given as mean with SD in parenthesis. n    9 for
determination of B cell numbers in the spleen of adult mice; n   4 for
all other determinations, except the mutant peritoneum where n   3.
aFractions assessed using the criteria of Hardy. Significant differences are
highlighted in bold, significance assessed by Student’s t test.
bP   0.02.
cP   0.001.
dP   0.02.757 Clayton et al.
ylation of I B  that was blocked by the PI3-K inhibitor
wortmannin (Fig. 4 F). B cells from p110 -deficient mice
did not show detectable phosphorylation of I B  after
BCR stimulation (Fig. 4 F). Bcl-xL levels in freshly isolated
B cells from mutant mice were lower than control cells
(Fig. 4 G). Furthermore, when cultured for 24 h in the
presence of antibodies to the BCR, Bcl-xL levels increased
in control but not in p110 -deficient B cells (Fig. 4 G).
p110  Is Required for Normal Function of Btk and
PLC 2. The mobilization of intracellular calcium (Ca2 )
after the addition of antibodies against IgM was reduced in
p110  /  B cells at all doses of agonist tested (Fig. 5 A).
This was evident in both the initial peak response and the
sustained response. To further evaluate the level at which
calcium mobilization was impaired we measured BCR in-
duced production of inositol 3,4,5 trisphosphate (IP3), the
second messenger that triggers calcium release from intra-
cellular stores. BCR stimulation of IP3 production was re-
duced in p110  /  B cells (Fig. 5 B). This observation
could reflect defective activation of PLC 2, as this lipase
requires phosphorylation by Btk, a tyrosine kinase whose
activity is dependent on PIP-3. Therefore, we measured
the phosphorylation and activation of Btk using phosphor-
ylation-site specific mAbs. In control mice Btk was phos-
phorylated on tyrosine 551 in response to BCR cross-link-
ing (Fig. 5 C). This reflects phosphorylation in trans by Src
and Syk family kinases (31–33). By contrast, phosphoryla-
tion of tyrosine 551 was not detected in p110 -deficient B
cells. Tyrosine 223 is a major autophosphorylation site of
Btk, its phosphorylation can thus be used as an indicator of
whether Btk has become activated. B cells from p110  / 
mice showed no detectable phosphorylation of Btk at posi-
tion 223. These results suggest that Btk activation requires
the function of p110 . Within PLC 2 tyrosines 753 and
759 have been identified as important Btk substrates (34,
35). To establish whether PLC 2 was phosphorylated by
Btk on tyrosine 759 we employed a phosphospecific mAb.
BCR stimulation of control B cells induced phosphoryla-
tion of PLC 2 on tyrosine 759, however there was little
phosphorylation of this residue in stimulated B cells from
p110 -deficient mice.
Discussion
B cells from mice deficient in p110  produce little PIP-3
after BCR engagement. This finding indicates that p110  is
mainly responsible for the bulk of PIP-3 production down-
stream of the BCR and that the p110  and   subunits, al-
though expressed at normal levels in p110 -deficient B
cells, cannot compensate for loss of p110 . This suggestion
is further substantiated by the observations that the well
characterized PI3-K effectors Btk and PKB are not, or only
weakly, activated in response to BCR stimulation in
p110 -deficient B cells. Our results do not exclude roles for
Figure 2. Lack of B1 and MZ B cells. (A) FACS® plot of scatter gated peritoneal cells
stained with the indicated combinations of monoclonal antibodies. The gates in the top
panel were used to generate the plots in the bottom panels which reveal the B1a, B1b, and
B2 subsets. A proportion of B cells in the wild–type are B220high CD5 , which are also
missing in the mutant. (B) Splenic cells were stained with the indicated combinations of
mAbs to reveal MZ and follicular B cell profiles. Numbers indicate the percentage of lympho-
cytes falling within the gate. These gates were used to calculate the numbers of cells in Table
I. (C) Immunofluorescence performed on splenic cryosections using MOMA-1 (green) and
anti-IgM (red) revealed a marked reduction in MZ B cells in p110  /  mice (right). The
position of MZ B cells is arrowed. The results shown are representative of four mutant
spleens examined. Original magnification: 200 .758 p110  in B Cell Homeostasis and Function
the p110  and   subunits in BCR signal transduction be-
cause weak phosphorylation of PKB could be detected in
p110  /  B cells after high levels of BCR cross-linking.
Furthermore, the PI3-K inhibitor wortmannin was able to
mediate additional inhibition of BCR-stimulated calcium
flux in p110  /  B cells (unpublished data). Our measure-
ments of total cell PIP-3 do not take account of small,
highly localized, concentrations of PIP-3 that may be gen-
Figure 3. Immune function in p110  mutant mice. (A) Serum Ig levels in naive
mice were measured by ELISA. (B) DNP-specific Ig of the indicated isotypes were
determined by ELISA of “preimmune” collected before immunization, and “immune”
sera collected 7 d after immunization with DNP-Ficoll. (C) DNP-specific Ig was
measured in preimmune serum, and in serum taken 7 and 21 d after immunization
with DNP-KLH. Mice were then reimmunized at 21 d and bled 7 d later to measure
the secondary response. In each set of graphs, the relative unit (absorbance) value
for individual control animals is represented by a filled circle, individual p110 -deficient
mice are represented by open circles. Bars represent the average and SD for the group.
In the TD responses, arrows represent the points at which mice were immunized (days
1 and 21). P values denote the levels of significance between sera of control and
p110  /  mice as determined by the Student’s t test. a, P   0.01; b, P   0.05; c,
not significant; d, P   0.001. (D) Quantitation of germinal center formation in
spleens taken 10 d after immunization. The results are expressed as the ratio of
PNA  germinal centers/B220  follicles. Black bar, wild type; white bar, mutant.
Data was compiled from two control mice and four mutant mice. (E) Flow cytometric
analysis of lymphocytes from Peyer’s patches. Activated B cells are gated as B220  GL7 ,
the numbers refer to the percentage of lymphocytes falling within the indicated gate.759 Clayton et al.
erated (36). Methodological limitations preclude our mea-
suring the spatio-temporal accumulation of PIP-3 in pri-
mary B cells, but such measurements will greatly increase
our understanding of PI3-K function in B cell signaling.
We have also noted a difference in B cell phenotype be-
tween p110 -deficient mice and mice deficient in the p85 
or p85/p55/p50  adaptor subunits of PI3-K (8, 9). Unlike
p85  and p85/p55/p50 -deficient mice, the spleens of
adult p110 -deficient mice contain normal numbers and
proportions of IgMlo IgDhi RF B cells. These observations
presumably reflect the participation of the p110  or   sub-
units, coupled via the p85  adaptor, into a pathway that
regulates the maturation of RF B cells. Alternatively, there
may exist additional functions for the p85  subunit that are
independent of the catalytic subunits. The functional inter-
relationships between the catalytic and regulatory subunits
are poorly understood in complex systems, as exemplified
by the phenotype of P85 -deficient mast cells. These cells
display reduced expression of p110  but normal levels of
p110  and   (37). Intriguingly, c-kit signaling is impaired
in P85 -deficient mast cells, whereas signaling through the
high affinity IgE-receptor (that is also dependent on PI3-K
activation) is normal (37, 38). Taken together with studies
using manipulated cell lines (39), these data argue for selec-
tive roles for the individual p110 catalytic subunits.
Our results show that p110  is required for the develop-
ment and/or survival of the B1 and MZ B cell subsets. A
number of previous studies have highlighted similarities be-
Figure 4. Proliferation and apoptosis of p110  /  B cells. (A) Purified splenic B cells
were cultured for 72 h with the indicated doses of polyclonal F(ab)2 goat anti–mouse IgM
with (squares) and without (circles) 100 U/ml recombinant murine IL-4. (B) B cells were
cultured for 72 h with media alone, or the indicated combinations of 6.25  g/ml mono-
clonal anti-IgM (clone B7.6), 6.25  g/ml monoclonal anti-CD40 (clone 3/23), and 100 U/ml
recombinant murine IL-4. Control B cells are the black symbols, mutant B cells the white
symbols. The numbers presented for each group represent counts per minute (cpm) plotted
as mean and SD. (C) Purified B cells were stimulated with the indicated amounts of F(ab)2
goat anti–mouse IgM for 2 min and lysed in SDS-PAGE sample buffer. Western blots were
developed with antibodies specific for PKB phosphorylated on serine 473 then stripped and
reprobed with a pan-PKB antibody (Cell Signaling Technology). (D) Time course of PKB
phosphorylation on serine 473 after stimulation with 10  g/ml F(ab)2 goat anti–mouse IgM. (E) B cells were cultured for 24 h in RPMI 1640 plus 10%
serum and apoptotic cells identified by flow cytometric analysis of DNA content using propidium iodide staining. Data are representative of B cells
from three mice of each genotype. (F) Defective I B  serine 32 phosphorylation, B cells were stimulated as in D and whole cell lysates blotted with
phosphospecific antibody, top panel, the blot was then stripped and reprobed with antibody to I B . On the right-hand side of the panel wild-type
B-lymphocytes were treated with 100 nM wortmannin (Wrtm.) before stimulation. (G) Bcl-xL levels were determined in freshly isolated B cells and
in B cells that had been stimulated for 24 h with 20  g/ml F(ab)2 goat anti–mouse IgM.760 p110  in B Cell Homeostasis and Function
tween these subsets, which appear to play important roles in
immunity through the production of natural antibodies, and
by being able to rapidly respond to antigenic challenge (40).
Indeed, the ability to mount T cell–independent type II anti-
gen responses has been attributed to MZ B cells (41). Our
finding that the levels of IgM and IgG3 in the serum of naive
mice were significantly reduced and that antibody responses to
DNP-Ficoll were severely impaired is consistent with the
properties of these cells. We found that p110  was required
for the generation of normal numbers of B2 B cells, particu-
larly in young mice, but not their maturation. Taken together
with the increased tendency of p110  /  B cells toward apop-
tosis this observation may reflect increased turnover of B2
cells. Confirmation of this will require further experimenta-
tion. The response to TD antigen, which is principally medi-
ated by B2 cells, was significantly impaired in both the primary
and secondary immune response. Although we observed a
modest primary antigen-specific IgM response, there was no
detectable class switching to IgG1 and severely impaired
switching to the other IgG subtypes. Consistent with this, ger-
minal center formation was profoundly impaired. The pheno-
type of p110  /  mice shows similarities with CD19 /  mice
that also lack B1 and MZ B cells, but have apparently normal
development of B2 cells which display impaired function (42–
44). However, splenic B cells from CD19 /  mice are less se-
riously impaired in their ability to activate PKB (45, 46) and
Btk (47) than are p110  /  B cells. It will be interesting to de-
termine whether CD19 employs p110  as a signal transducer.
The defective proliferation of p110  /  B cells to anti-CD40 is
also a feature shared with CD19 /  B cells (48) and suggests that
the mutant B cells may be unable to respond to T cell help.
CD40 ligation on B cells activates PI3-K (49), and CD40-
mediated B cell proliferation is blocked by PI3K inhibitors or
p85  deficiency (8, 9). Preliminary experiments suggest CD86
upregulation is also defective in p110  /  B cells (unpublished
data), therefore cognate T–B interactions required for the nor-
mal humoral response may be defective. It will also be inter-
esting to determine whether the ability of p110  /  T cells to
provide help is defective. p110  was not required for mitoge-
nic responses to all stimuli, as 110  /  B cells proliferated nor-
mally in response to LPS which also activates PI3-K (50) and
requires the function of p85  to exert its mitogenic effect (8,
9). Our results thus suggest that catalytic subunits other than
p110  may be mediating the mitogenic LPS signal. IL-4–
mediated proliferation is also sensitive to PI3-K inhibitors and
requires p85  function (8, 9). p110  does not appear to be re-
quired for IL-4 costimulation of proliferation induced by anti-
IgM, as this was generally of a similar magnitude in both
wild-type and p110  /  B cells. Furthermore, preliminary
experiments determining the ability of IL-4 to mediate sur-
vival of cultured B cells has not revealed a difference be-
tween wild-type and p110  /  B cells (unpublished data).
Figure 5. Defective calcium signaling pathway in p110  /  B cells. (A) Intracellular
calcium concentration in B cells after addition of F(ab)2 goat anti–mouse IgM, (indicated
by arrow). Wild-type is thick black line and mutant thin line. (B) IP3 production was
measured in control (black symbol) and mutant (white symbol) B cells after stimulation
with 33  g/ml F(ab)2 goat anti–mouse IgM using a kit purchased from New England
Nuclear. The values represent the mean and SD of determinations from B cells from four
individual mice. (C and D) Purified B cells were stimulated with 10  g/ml F(ab)2 goat
anti–mouse IgM for the indicated times and Btk immunoprecipitates blotted with anti-
bodies specific for phosphorylated tyrosine 551 (C) or 223 (D). Blots were stripped and
reprobed with polyclonal anti-Btk to demonstrate equal recovery of proteins. (E) Defective
phosphorylation of PLC 2. Whole cell lysates from purified B cells stimulated for 1 min with
the indicated amounts of F(ab)2 goat anti–mouse IgM were blotted with antibody specific to phosphorylated tyrosine residue 759 of PLC 2. The blot
was then stripped and reprobed with antisera specific to PLC 2 to confirm loading. The arrow indicates the position of phospho-PLC 2.761 Clayton et al.
PI3-K signaling has been intimately linked with cell sur-
vival in a number of systems by virtue of its ability to regu-
late PKB (28). p110 -deficient B cells were impaired in
their ability to survive after in vitro culture and expressed
less of the antiapoptotic protein Bcl-xL. After activation
through the BCR p110 -deficient B cells failed to appre-
ciably activate PKB and also displayed defective phosphor-
ylation of I B . In addition, the increased expression of
Bcl-xL that follows BCR stimulation required the function
of p110 . Taken together, these results are consistent with
the suggestion that p110  is important for the activation of
survival pathways in B cells.
A number of studies have described mice lacking com-
ponents of the BCR signaling pathway that share B cell de-
velopmental phenotypes. These include xid mice as well as
mice deficient in Btk, B cell linker protein, PLC 2, Vav-
1/Vav-2, and B cell adaptor for PI3-K (BCAP) (51). The
similarities in phenotypes between these mice, taken to-
gether with evidence of physical association, has led to the
suggestion that these molecules act as a molecular machine
or “signalosome” (52, 53). One model for BCR activation
of calcium flux places emphasis on Btk-mediated phos-
phorylation and activation of PLC 2. Activation of Btk is
dependent on PI3-K (12, 54), as PIP-3 regulates Btk func-
tion by regulating both the location (55, 56) and the cata-
lytic activity of Btk (57). Our data are consistent with such
a model as we found that Btk was not phosphorylated and
activated as assessed using phosphospecific antibodies. In
addition, we found PLC 2 phosphorylation and activation
was defective in p110  /  B cells. A recent study also im-
plicated p110  in the regulation of PLC 2 function in
Fc RI-stimulated RBL-2H3 cells by injecting p110 -spe-
cific inhibitory antibodies (58). Besides activation of Btk,
additional PIP-3–mediated mechanisms may contribute to
PLC 2 activation as PIP-3 has been reported to bind di-
rectly to and activate PLC 2 (58–60). Taken together, our
results suggest that p110  is the key PI3-K catalytic subunit
required for the function of the signalosome in B cells.
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